SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Infinity Pharmaceuticals, Inc. (Nasdaq – INFI)

BALA CYNWYD – February 23, 2023 /Newsfile/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”) (Nasdaq – INFI) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the Company’s agreement to merge with MEI Pharma, Inc. (“MEI”) (Nasdaq: MEIP). Under the terms of the merger agreement, Infinity will become a wholly owned subsidiary of MEI. Pursuant to an exchange ratio set forth in the merger agreement, pre-merger MEI shareholders are expected to own approximately 58.0% and pre-merger Infinity shareholders are expected to own approximately 42.0% of the outstanding equity of the combined company immediately following the merger.

The investigation concerns whether the Infinity Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to Infinity shareholders in the combined company.

If you own shares of Infinity stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.